<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622214</url>
  </required_header>
  <id_info>
    <org_study_id>0400-21-RMB</org_study_id>
    <nct_id>NCT05622214</nct_id>
  </id_info>
  <brief_title>The Efficacy and Tolerability of 12-weeks Treatment With Almond and Buckwheat Based Formula in Pediatric Patients With Active EoE</brief_title>
  <official_title>An Open Label, Pilot Study Assessing the Efficacy and Tolerability of 12-weeks Treatment With Almond and Buckwheat Based Formula in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Else Nutrition GH Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eosinophilic esophagitis (EoE) is a chronic, relapsing, immune-mediated esophageal disease.&#xD;
      Clinical manifestations in infants and toddlers generally include vomiting, food refusal,&#xD;
      choking with meals and, less commonly, failure to thrive. The management of the disease&#xD;
      includes dietary and pharmaceutical interventions, and the goal of the treatment should&#xD;
      ideally be both the resolution of symptoms and the normalization of the macroscopic and&#xD;
      microscopic abnormalities. Milk is the most common food trigger identified, followed by&#xD;
      wheat, soy, and eggs. The aim of the study is to examine the tolerability of a new plant&#xD;
      based formula made of minimally processed almond and buckwheat and enriched with vitamins and&#xD;
      minerals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 24, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Pediatric Eosinophilic Esophagitis Symptom Severity Module (PEESS), endoscopic and histological scoring</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement in PEESS, endoscopic and histological scoring (assessed at week 0 and week 12)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Plant based nutrition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plant based nutritional formula based on almond and buckwheat</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Else nutrition formula</intervention_name>
    <description>Plant based nutrition from almond and buckwheat</description>
    <arm_group_label>Plant based nutrition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients with active EoE (na√Øve and experienced)&#xD;
&#xD;
          -  Ages 1-18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Change in dosing of Proton pump inhibitors (PPI) medication&#xD;
&#xD;
          -  Local steroid treatment &lt; 1 month&#xD;
&#xD;
          -  Refusal to comply with study protocol&#xD;
&#xD;
          -  Known allergy to almonds and buckwheat&#xD;
&#xD;
          -  Use of dairy during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Shaoul, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ron Shaoul, Dr.</last_name>
    <phone>+972-4-7774381</phone>
    <email>r_shaoul@rambam.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liat Pritzker</last_name>
    <phone>+972-4-7774381</phone>
    <email>l_perel@rambam.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ron Shaoul, Dr.</last_name>
      <phone>+972-4-7774381</phone>
      <email>r_shaoul@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Ron Shaoul MD</investigator_full_name>
    <investigator_title>Director, Pediatric Gastroenterology institute</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

